Subscribe
logo-tag-line
Courtesy of Aurobindo Pharma
4 July 2014Americas

Aurobindo sued by Pfizer over skin antibiotic

Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Biofrontera settles patent dispute with Dusa over skin treatment
30 November 2021   A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Americas
Pfizer to settle Xeljanz suit with Teva
9 September 2021   Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Biofrontera settles patent dispute with Dusa over skin treatment
30 November 2021   A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Americas
Pfizer to settle Xeljanz suit with Teva
9 September 2021   Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

More on this story

Americas
Biofrontera settles patent dispute with Dusa over skin treatment
30 November 2021   A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Americas
Pfizer to settle Xeljanz suit with Teva
9 September 2021   Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB